-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Benzinga·09/22/2026 16:05:03
Diffusion vocale
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.